


FORM PTO-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER 47-165
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/031492 Undesignated
INTERNATIONAL APPLICATION NO. PCT/AU00/00873	INTERNATIONAL FILING DATE 20 July 2000	PRIORITY DATE CLAIMED 20 July 1999
TITLE OF INVENTION NEUROTROPIC VIRUS TRANSPORT		
APPLICANT(S) FOR DO/EO/US DIEFENBACH et al		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The U.S. has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 To 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information. 		

10031492-06 1002
JC13 Rec'd PCT/PTO 22 JAN 2002

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.492(a)(1)-(5)) Unassigned 10031492-06		INTERNATIONAL APPLICATION NO. PCT/AU00/00873		ATTORNEY'S DOCKET NUMBER 47-165	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5): -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1040.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$740.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	1040.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20	-20 =	0	X	\$18.00
Independent Claims	2	-3 =	0	X	\$84.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)					\$280.00
TOTAL OF ABOVE CALCULATIONS =				\$	1170.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					0.00
SUBTOTAL =				\$	1170.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).				+	0.00
TOTAL NATIONAL FEE =				\$	1170.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				+	0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1280.00 - Small Entity = \$640.00)				\$	0.00
TOTAL FEES ENCLOSED =				\$	1170.00
				Amount to be:	
				refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1170.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.					
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYTE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000					
				 SIGNATURE	
				Leonard C. Mitchard NAME	
				29,009 REGISTRATION NUMBER	
				January 22, 2002 Date	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DIEFENBACH et al

Atty. Ref.: 47-165

Serial No. Unassigned

Group:

Filed: January 22, 2002

Examiner:

For: NEUROTROPIC VIRUS TRANSPORT

* * * * *

January 22, 2002

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for examination, please amend the application as follows:

IN THE CLAIMS

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

4. (Amended) The method according to claim 1 comprising providing to a neuron or cell a compound capable of altering or preventing interaction between a structural tegument protein of a neurotropic virus and a motor protein in the neuron or cell.

11. (Amended) A method according to claim 1, wherein the method prevents or reduces transport of a neurotropic virus within a neuron.

15. (Amended) The antiviral composition according to claim 12 wherein the compound a motor protein-like molecule which binds to a structural tegument protein of the virus thereby preventing the normal interaction of the virus and neuron or cell.

18. (Amended) The antiviral composition according to claim 12 wherein the compound is a structural tegument-like molecule which binds to a motor protein of a neuron thereby preventing the normal interaction between the neuron or cell with the virus.

REMARKS


The above amendments have been made to place the application in a more traditional format. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned

"Version With Markings To Show Changes Made."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

4. (Amended) The method according to [any one of claims 1 to 3] claim 1 comprising providing to a neuron or cell a compound capable of altering or preventing interaction between a structural tegument protein of a neurotropic virus and a motor protein in the neuron or cell.

11. (Amended) A method according to [any one of claims 1 to 10] claim 1, wherein the method prevents or reduces transport of a neurotropic virus within a neuron.

15. (Amended) The antiviral composition according to [any one of claims 12 to 14] claim 12 wherein the compound a motor protein-like molecule which binds to a structural tegument protein of the virus thereby preventing the normal interaction of the virus and neuron or cell.

18. (Amended) The antiviral composition according to [any one of claims 12 to 14] claim 12 wherein the compound is a structural tegument-like molecule which binds to a motor protein of a neuron thereby preventing the normal interaction between the neuron or cell with the virus.

5/prls

1

NEUROTROPIC VIRUS TRANSPORT

Technical Field

The present invention relates to viral infections, particularly cellular and tissue interactions during infection.

Background Art

Little is known about the mechanisms of transport of neurotropic viruses, such as Herpes simplex virus (HSV), varicella-zoster virus and rabies, within neurones. For these viruses, which replicate in the nucleus, anterograde transport from the cell body of dorsal root human ganglionic (DRG) neurons to the axon terminus occurs over long distances. In the case of HSV, there is increasing evidence for separate, fast anterograde axonal transport of viral nucleocapsids coated with tegument along microtubules (MTs) and of glycoproteins in axonal transport vesicles. An understanding of the mechanisms of transport of these viruses would be of benefit. Once this information is obtained, means to interrupt or prevent this transport would be a good candidate for antiviral therapy.

HSV consists of an outer lipid envelope containing glycoproteins which surrounds the tegument. The inner capsid encloses the viral DNA to form the nucleocapsid. Early work has shown that HSV retrograde axonal transport in rat neurons utilizes microtubules (K. Kristensson, E. Lycke, J. Sjostrand, *Acta Neuropathol.* 17. 44. 1971). Previously, the present inventors have used a two chamber system to examine the mechanism of anterograde transport of HSV from infected dorsal root ganglionic (DRG) neurones in the central chamber along axonal fascicles to epidermal explants in the outer chamber. The velocity of viral transport (0.6 $\mu\text{m/s}$) indicated a mechanism based on fast anterograde transport (M. E. Penfold, P. Armati, A. L. Cunningham, *Proc. Natl. Acad. Sci. USA* 91, 6529, 1994). Using freeze-substitution transmission immuno-electron microscopy (TIEM) the virus was shown to be transported as unenveloped nucleocapsids, coated with tegument, separately from glycoproteins which are transported in vesicles (D. J. Holland, M. Miranda-Saksena, R. A. Boadle, P. J. Armati, A. L. Cunningham, *J. Virol.* 73, 8476, 1999). These findings were supported by experiments with nocodazole, an inhibitor of microtubule polymerization, and brefeldin A which inhibits transport through the Golgi. The transport of

all three viral components, nucleocapsid, tegument and glycoproteins was inhibited by nocodazole, indicating their dependence on microtubule-associated transport. Brefeldin A, however, inhibited glycoprotein transport but not nucleocapsids confirming that the two are transported along separate pathways and indicating the close association of HSV glycoproteins with Golgi/intermediate compartment membranes.

The present inventors have now obtained useful evidence for the direct interaction between a viral structural tegument protein and an ubiquitous cellular protein. This new information has been used to develop methods and compositions to alter viral transport and movement in cells.

Disclosure of Invention

In a first aspect, the present invention provides a method of preventing or reducing transport of a neurotropic virus within a neuron or cell, the method comprising providing to said neuron or cell a compound preventing binding between a structural tegument protein of the virus and a motor protein in the neuron or cell such that virus transport in the neuron is prevented or reduced.

In a preferred embodiment, the neurotropic virus is Herpes simplex virus (HSV), varicella-zoster virus, or rabies virus. More preferably, the virus is HSV, the structural tegument protein is US11, and the motor protein is kinesin.

The method according to the invention can be carried out by providing a compound to a neuron or cell capable of preventing binding between a structural tegument protein of a neurotropic virus and a motor protein in a neuron or cell.

In one preferred form, the compound is a motor protein-like molecule which binds the structural tegument protein thereby preventing the normal interaction of the virus with cellular motor protein.

The motor protein-like molecule can be any suitable molecule and would include mimics of the motor protein or a parts of the motor protein to which the structural tegument protein binds.

When the motor protein is kinesin in the case of HSV, the kinesin-like molecule can be any suitable molecule and would include mimics of kinesin or a parts of kinesin to which the structural tegument protein US11 of HSV binds.

In another preferred form, the compound is a structural tegument-like molecule which binds to a motor protein of a neuron or cell thereby preventing the normal interaction between the neuron or cell with the virus. The structural tegument-like molecule can be a mimic of a viral tegument protein or a part of the tegument protein to which a cellular motor protein binds. Preferably, the virus is Herpes simplex virus, the structural tegument protein is US11, motor protein is kinesin and the structural tegument-like molecule is a mimic of US11 or a part of US11 to which the motor protein kinesin binds.

Knowing how these types of viruses move in neurons to infect neurons other cells and ultimately form lesions is an important advance and is useful for the development of antiviral strategies. Usually, during the latent state these viruses do not cause any real problems to an individual. It is during the active phase of the virus where clinical manifestations occur and suffering is caused. Preventing the actual transport of the virus down infected neurons should at least combat or prevent the clinical symptoms of re-infection. Similarly, preventing movement up the neuron may prevent the formation of latent state of the virus in ganglia or at least reduce the incidence of re-occurrence of manifestations of the disease in infected individuals.

In a second aspect, the present invention provides a modified neurotropic virus which has lost or has reduced ability to be transported in neurons, the virus comprising a mutation in a tegument protein such that the mutated tegument protein has abnormal interaction with a cellular motor protein.

In a third aspect, the present invention provides use of a compound to prevent or reduce the interaction between a neurotropic viral tegument protein with a cellular motor protein to prevent or reduce viral transport in a neuron.

In a preferred embodiment of the second and third aspects of the present invention, the neurotropic virus is Herpes simplex virus (HSV), varicella-zoster virus, or rabies virus. More preferably, the virus is HSV, the structural tegument protein is US11, and the motor protein is kinesin.

In a fourth aspect, the present invention provides an antiviral composition comprising a compound capable of preventing

binding between a structural tegument protein of a neurotropic virus and a motor protein in a neuron.

Preferably, the neurotropic virus is selected from the group consisting of Herpes simplex virus, varicella-zoster virus, and rabies virus.

5 Preferably, the virus is Herpes simplex virus, the structural tegument protein is US11, and the motor protein is kinesin.

In one preferred form, the compound is a motor protein-like molecule which binds to the structural tegument protein of the virus thereby preventing normal interaction of the virus with cellular motor protein of a
10 neuron. Preferably, the motor protein-like molecule comprises a mimic of a cellular motor protein or a part of the motor protein to which a structural tegument protein of a virus binds.

In a further preferred form, the virus is Herpes simplex virus, the motor protein is kinesin and the motor protein-like molecule is a mimic of
15 kinesin or a part of kinesin to which the structural tegument protein US11 of Herpes simplex virus binds.

In another preferred form, the compound is a structural tegument-like molecule which binds to a motor protein of a neuron or cell thereby preventing the normal interaction between the neuron or cell with the virus.
20 The structural tegument-like molecule can be a mimic of a viral tegument protein or a part of the tegument protein to which a cellular motor protein binds. Preferably, the virus is Herpes simplex virus, the structural tegument protein is US11, motor protein is kinesin and the structural tegument-like molecule is a mimic of US11 or a part of US11 to which the motor protein
25 kinesin binds.

The composition can further include additives, diluents, excipients and the like which can be used in clinical and health situations.

This study raises many questions about the mechanisms of tegument formation, location of US11 in the tegument of HSV, the potential role of
30 motor proteins other than kinesin(s) and homologous interactions mediating the transport of other neurotropic viruses. Studies to map minimal binding regions of US11 and uKHC and identification of other cellular factors which facilitate or contribute to the interaction will be useful. Inhibition of this interaction by peptides and/or peptidomimetic analogues could provide a
35 new strategy for antiviral treatment for this and other neurotropic viruses. Incorporation of deletions into specifically attenuated live HSV (or other

attenuated live neurotropic viruses) vaccine candidates could also be useful to prevent clinical recrudescence.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples and drawings.

Brief Description of Drawings

Figure 1. Transmission immuno-electron micrographs of human fetal axons labelled with 5 and 10 nm immunogold particles recognising HSV major capsid protein VP5 and the stalk of human uKHC respectively. Arrows = 5 nm gold particles. Arrowheads = 10 nm gold particles. Bars = 200 nm (A and C) or 100 nm (B).

A Clustering of immunogold label for uKHC around axonal vesicles and diffuse labelling of other axons. Labelling with preimmune sera produced only sparse background label.

B Colocalization of the two immunogold labels against uKHC and VP5 over a dense unenveloped viral particle in an axon. Arrows = VP5 (5 nm gold particle).

C Extracellular virus labelled only with anti-VP5. In the upper right corner is an axon with diffuse 10 nm immunolabel against uKHC. There is no immunolabel for uKHC over extracellular virus with only sparse background label outside axons.

Figure 2. Identification of kinesin-binding HSV1 proteins. Mock or virus-infected Hep-2 cell lysates were incubated, as indicated (+), with His-KHC fragments bound to nickel-activated beads. Eluted kinesin-viral protein complexes were analysed by immunoblotting with appropriate antibodies.

A Polyclonal antibody to HSV1 identified major viral bands at 65 and 20 kDa bound preferentially to His-KHCstalk/tail.

B-C The viral proteins were identified with monoclonal antibodies as VP16 (B) and US11 (C), respectively. In each immunoblot, the first two lanes are controls for antibody specificity.

Figure 3. Direct binding of US11 to uKHC and VP16. Shown are immunoblots of protein complexes eluted from nickel-activated beads.

- A Lysates of bacteria expressing untagged KLC or US11 were incubated, as indicated (+), with His-KHC fragments. US11 bound only to His-KHCstalk/tail in the absence of other HSV1 proteins (lane 2, bottom panel). Overnight preincubation of the His-KHC fragments with KLC, which binds only to His-KHCstalk/tail (lane 4, top panel), prior to addition of US11, also showed binding of US11 but this was slightly reduced (lane 4, bottom panel).
- B In a similar experiment, recombinant untagged VP16 did not bind to either His-KHC fragment (lanes 2 and 3). Expression of VP16 in bacterial lysates was confirmed in lane 1. Native VP16 from HSV1-infected Hep-2 cells (lanes 4 and 5) or recombinant untagged VP16 (lanes 6 and 7) was incubated with His-US11 or His-KHCstalk. Both forms of VP16 interacted with His-US11.

- Figure 4. Transport of structural HSV antigens into axons of infected dissociated rat neonatal neurons *in vitro*. Dissociated DRG neurons were infected with either wt HSV1 (CW strain), a US11 deletion mutant of HSV1 (R6604) or a US11 rescuant of R6604 (R6606) at 20 pfu/neuron. The appearance and transport into the principle axon of HSV1 tegument (US11), nucleocapsid (VP5) and envelope glycoprotein (gC) antigens was followed by serial fixation over 6 to 36 h, and then immunofluorescence and confocal microscopy. (A-I) HSV1 antigens in the axon at 24 h post infection (hpi). Bars = 10 μ m (A and C) or 25 μ m (B and D-I). US11 was present in axons infected with wt HSV1 (A) but was completely absent from neurons infected with R6604 (B). US11 was expressed in neurons and present in axons infected with R6606 (C). VP5 was present in axons infected with wt HSV1 (D) but was not detected in axons infected with R6604 (E). VP5 was present in axons infected with R6606 (F). gC was detected in axons whether infected with wt HSV1 (G), R6604 (H) or R6606 (I).

- Figure 5. Ultrastructural distribution of enveloped and unenveloped nucleocapsids from an HSV1 US11 deletion mutant (R6604) in dissociated rat DRG neurons (26 hpi).

A Unenveloped (arrow) and enveloped (arrow head) nucleocapsids adjacent to the Golgi (G) within the cytoplasm of the cell body.

B Enveloped virions (arrow) in the extracellular space adjacent to the cell body and longitudinal section of an axonal process (arrowhead) containing microtubules.

Modes for Carrying Out the Invention

5 METHODS

Antibody

HisKHC555-772, a oligohistidine (His)-tagged fragment of human uKHC (R. J. Diefenbach, J. P. Mackay, P. J. Armati, A. L. Cunningham, *Biochemistry* 37, 16663, 1998), was used to generate chicken polyclonal anti-
10 uKHC. The cell pellet from a 1 litre bacterial culture expressing HisKHC555-772 was resuspended in 25 ml of column running buffer (20 mM sodium diphosphate, pH 7.4, 0.5 M NaCl), lysed by sonication, clarified by centrifugation, and applied to a POROS 20 MC column (Perseptive Biosystems; 4.6 x 10 mm) which had been charged with nickel according to
15 the manufacturer's instructions. The His-tagged fusion protein was eluted at 5 ml/min with 15 column volumes of a gradient from 0 to 0.5 M imidazole in running buffer. Pooled fractions containing purified HisKHC555-772 were then dialysed against PBS. Protein concentrations were determined using a Bio-Rad protein assay. A total of 2 mg of protein was then used to raise a
20 polyclonal antibody in chickens (a service provided by the Institute of Medical and Veterinary Science, Veterinary Services Division, Gilles Plains, South Australia). Pre- and post-immune serum from a single immunised chicken was subsequently used in this study. The antibody was shown to be specific in immunoblots for human uKHC by comparing reactivity with the
25 immunising antigen against human neuronal (n) KHC (expressed as a His-tagged fragment spanning amino acids 409-1032). cDNAs for uKHC (F. Navone, *et al.*, *J. Cell Biol.* 117, 1263, 1992) and nKHC (J. Niclas, F. Navone, N. Hom-Booher, R. D. Vale, *Neuron* 12, 1059, 1994)) were provided by R. Vale.

30 HisKHC Proteins

The HisKHC proteins were expressed, harvested, bound to, and eluted from nickel-activated beads as previously described (R. J. Diefenbach, J. P. Mackay, P. J. Armati, A. L. Cunningham, *Biochemistry* 37, 16663, 1998). Generation of virus stocks and titrations of wt HSV1 (CW1) and modified
35 viruses were performed in Hep-2. For binding assays, Hep-2 cells were infected at a multiplicity of 5 pfu/cell and incubated for 24 h. Cell

monolayers were washed twice with PBS, resuspended in PBS (1×10^6 cells/ml), freeze-thawed 3 times, sonicated for 15 s, before addition of 1% (v/v) NP-40 and incubation for 1 h at 4°C. The soluble fraction was harvested by centrifugation at 4°C (10000g for 15 min) before addition (1 ml) to HisKHC fragments on nickel-activated beads. Beads were incubated overnight with rocking at 4°C, washed with 3 x 20 volumes of wash buffer (150 mM NaCl, 120 mM imidazole, 20 mM Tris-HCl, pH 7.9), prior to elution of bound protein complexes. Protein complexes were separated by SDS-PAGE and identified by immunoblotting as previously described (R. J. Diefenbach, J. P. Mackay, P. J. Armati, A. L. Cunningham, *Biochemistry* **37**, 16663, 1998). Antibodies used included mouse monoclonal anti-US11 (R. J. Roller, B. Roizman, *J. Virol.* **66**, 3624, 1992) (provided by B. Roizman), mouse monoclonal anti-VP16 (C. McLean, *et al.*, *J. Gen. Virol.* **63**, 297, (1982) (LP1; provided by T. Minson) and rabbit polyclonal anti-HSV1 from Dako. Rabbit polyclonal antibody to HSV1 capsid protein VP5 was provided by G. Cohen and R. Eisenberg (G. H. Cohen, *et al.*, *J. Virol.* **34**, 521, 1980). Mouse monoclonal antibody to HSV1 gC and KLC (L2) was obtained from Chemicon International.

Plasmids

Plasmid pRB4766 (H. Tsiang, E. Lycke, P. E. Ceccaldi, A. Ermine, X. Hirardot, *J. Gen. Virol.* **70**, 2075, 1989) containing HSV1 US11 genomic DNA in pGEX-KG was provided by B. Roizman. An untagged US11 construct was generated by digestion of pRB4766 with *NcoI* and insertion into the *NcoI* site of pET-28a. This resulted in an additional five amino acids (MGRLE) at the N-terminus of US11. His-tagged US11 was constructed by inserting an *EcoRI/FspI* US11-containing fragment from pRB4766 into *EcoRI/HindIII* (Klenow filled-in) digested pET-28c. Between the oligohistidine tag and US11 sequence are inserted amino acids LDSMGRLE. Genomic DNA containing HSV1 VP16 was provided by P. O'Hare (T. A. Hughes, S. La Boissiere, P. O'Hare, *J. Biol. Chem.* **274**, 16437, 1999; D. O'Reilly, O. Hanscombe, P. O'Hare, *EMBO J.* **16**, 2420, 1997). The plasmid pPO54 consisted of the gene for VP16 inserted into the *BamHI* site of pBS. An untagged VP16 construct was generated by firstly digesting pPO54 with *BamHI* and inserting into the *BamHI* site of pET-28c. VP16 was subsequently released from pET-28c by digestion with *BamHI/XhoI* and inserted into the yeast vector pACT2 also cut with *BamHI/XhoI*. VP16 was then released with

an *NcoI/XhoI* digest and reinserted into the *NcoI/XhoI* site of pET-28a to allow expression of untagged VP16. The resulting fusion protein had an additional nineteen amino acids (MEAPGIRDPRSSFPYQPHP) at the N-terminus of VP16. Bacteria expressing untagged US11, VP16 or KLC (R. J. Diefenbach, J. P. Mackay, P. J. Armati, A. L. Cunningham, *Biochemistry* 37, 16663, 1998) were lysed in normal salt binding buffer (150 mM NaCl, 5 mM imidazole, 20 mM Tris-HCl, pH 7.9) for use in binding assays as described above.

Virus Mutants

R6604 is a partial US11 gene deletion mutant which does not express the US11 protein and R6606 is US11 rescuant of R6604. To generate the HSV1 mutant R6604 (US11-), a plasmid carrying a deletion in the US11 coding sequence was constructed (pRB5173) by deleting the sequences present between *BspEI* and *XhoI* in the *BamHI* Z fragment of HSV1(F) genome. The 132 nucleotides deleted from the fragment removed all three ATG codons of the US11 ORF without affecting the adjacent US12 ORF. The plasmid was cotransfected with the R3630 recombinant virus DNA containing the thymidine kinase gene inserted into US12. The selected recombinant progeny (R6603) contained a US11 gene lacking the 132 nucleotides but an intact US12. The thymidine kinase gene at its natural locus was then restored to yield R6604. The genotype and phenotype of all recombinants was verified by Southern analysis and immunoreactivity of its proteins.

RESULTS

The candidate motor proteins for viral transport should be those involved in microtubule-dependent fast axonal anterograde transport of organelles, most likely the conventional kinesins (ubiquitous and neuronal) or possibly the kinesin-related protein KIF3. The colocalization of kinesin and HSV1 nucleocapsids was examined in fetal human neurons using the DRG neuron-epidermal explant two chamber model system as previously described (D. J. Holland, M. Miranda-Saksena, R. A. Boadle, P. J. Armati, A. L. Cunningham, *J. Virol.* 73, 8476, 1999). Anterograde axonal transport of HSV1 (CW strain; D. J. Holland, M. Miranda-Saksena, R. A. Boadle, P. J. Armati, A. L. Cunningham, *J. Virol.* 73, 8476, 1999) was visualized using freeze-substitution TIEM. Dual immunogold labelling (5 and 10 nm gold particles) of axons was performed with chicken polyclonal antibody to

ubiquitous kinesin heavy chain (uKHC) and rabbit polyclonal antibody to HSV1 major capsid protein VP5 (G. H. Cohen, *et al.*, *J. Virol.* **34**, 521, 1980).

Anti-uKHC showed diffuse labelling throughout axons with clusters of immunolabel for uKHC observed around electron dense axonal vesicles (Figure 1A). Only sparse background label was found extra-axonally. With pre-immune sera only sparse background immunolabel was present on sections and there was no labelling of axonal vesicles. Immunolabel for uKHC and VP5 was found in and around unenveloped HSV1 nucleocapsids, respectively, within axons (Figure 1B). The anti-VP5 antibody was specific with no labelling of axons in mock-infected cultures. Only VP5 and not kinesin immunolabel was present on extracellular virus (Figure 1C). The immunolabelling for uKHC over intra-axonal virus (but not extra-axonal virus) was as intense as that around axonal vesicles and provides strong direct evidence that kinesin is involved in the anterograde axonal transport of HSV. The tegument protein VP16 has been demonstrated to colocalize with VP5-labelled nucleocapsids during anterograde transport (D. J. Holland, M. Miranda-Saksena, R. A. Boadle, P. J. Armati, A. L. Cunningham, *J. Virol.* **73**, 8476, 1999). Therefore, tegument or outer capsid proteins are candidates for binding to conventional ubiquitous kinesin.

Conventional kinesin is a heterotetramer consisting of two identical heavy and two identical light chains. The heavy chain has a three domain structure consisting of a N-terminal motor domain, highly conserved among the kinesin superfamily, a central stalk domain containing heptad repeats and a C-terminal tail domain. The present inventors used fragments of human uKHC tagged at the N-terminus with an oligohistidine (His) sequence, which were generated and characterised previously, as bait to identify kinesin-binding HSV1 proteins. In this work, the fragments were designated His-KHCstalk (amino acid residues 555-772) and His-KHCstalk/tail (residues 771-963).

HisKHC fragments attached to nickel-activated beads were incubated with a lysate of mock or HSV1-infected Hep-2 cells. Analysis of eluted complexes by immunoblotting with anti-HSV1 identified predominantly a 65 and 20 kDa viral protein preferentially bound to KHCstalk/tail (Figure 2A). These viral proteins were subsequently identified as the tegument proteins VP16 (Figure 2B) and US11 (Figure 2C).

To establish whether US11 and/or VP16 bound directly to uKHC, untagged forms of both were expressed in *Escherichia coli*. Addition of untagged US11 to HisKHC showed that US11 binds specifically to KHCstalk/tail (Figure 3A, bottom panel). This also showed that the binding of US11 to uKHC can occur in the absence of other viral proteins although it may well be modulated *in vivo* by viral or cellular factors. A complex of uKHC and KLC was generated by preincubating HisKHCstalk/tail with untagged KLC (Figure 3A, top panel). This kinesin heavy/light chain complex also binds US11, though at a slightly reduced level when compared with heavy chain alone (Figure 3A, bottom panel lanes 2 and 4). The minor reduction in US11 binding is probably due to steric effects and not competitive inhibition since KLC and US11 bind to different regions of His-KHCstalk/tail. Therefore, KLC appears not to be directly involved in binding US11 as there was no increase in the level of US11 bound to a heavy/light chain complex compared with heavy chain alone. A similar observation has been documented using a KHCstalk/tail fragment from sea urchin which can bind to vesicles in the absence of KLC.

In contrast, VP16 does not bind directly to uKHC (Figure 3B). The presence of VP16 co-eluting with KHC after incubation with viral lysates can be explained by the observation that VP16 binds directly to US11 (Figure 3C). This binding was observed with both native and recombinant VP16 (in the absence of other viral proteins). Therefore uKHC binds US11 which in turn binds VP16. This VP16/US11 interaction may represent an important structural interaction for US11 in the tegument of the virus or may play a regulatory role in infected cells. VP16 has also been shown to bind to other tegument proteins including vhs (C. A. Smibert, B. Popova, P. Xiao, J. P. Capone, J. R. Smiley, *J. Virol.* **68**, 2339, 1994) and VP22 (G. Elliott, G. Mouzakis, P. O'Hare, *J. Virol.* **69**, 7932, 1995), as well as to glycoprotein (gD; Q. Zhu, R. J. Courtney, *Virology* **204**, 590, 1994). Therefore US11, a structural viral protein proposed to be part of the tegument, may also interact with one or both of these other tegument proteins.

US11 appears to be a multi-functional protein. It is a basic phosphoprotein which has RNA-binding activity, stably associates with 60S ribosomal subunits, has a role in post-transcriptional regulation of gene expression and localizes to the nucleoli. The RNA-binding properties of US11 are dependent on the 20-24 RXP-repeats in the carboxy-half of the

protein while the amino-half of US11 is required for transactivation of gene expression. It has been suggested that the N-terminal domain may be involved in transport and translation of mRNA from the nucleus to the cytoplasm. This amino domain may well also bind to kinesin. The US11
5 protein is well conserved between HSV1 and 2 (63% homology) with the greater variation at the N-terminus. There are no US11 homologues in varicella-zoster virus or rabies suggesting this virus may use different proteins for anterograde axonal transport. However, there are precedents though within the herpesviruses for similar functions on different proteins
10 (eg entry into cells *via* gD in HSV (J. Rajcani, A. Vojvodova, *Acta Virol.* **42**, 103, 1998) and *via* gE/I and gB in varicella zoster virus C; Grose, *Rev. Infect. Dis. Suppl.* **11**, S960, 1991).

To test the hypothesis that the US11-uKHC interaction mediated anterograde transport of HSV into the axons of rat neonatal DRG neurons, the
15 axonal transport of wild-type (wt) HSV1, a US11 deletion mutant of HSV1 and its rescuant were examined. The appearance and distribution of structural HSV protein antigens from the tegument (US11), nucleocapsid (VP5) and envelope (gC) and their anterograde transport into axons of dissociated rat neonatal DRG was followed by fixation at serial time points
20 over 24 hours and immunofluorescence/confocal microscopy.

Firstly, US11 antigen from wt HSV1 (CW clinical strain), was demonstrated to move down the axon (a criterion for its proposed role in anterograde axonal transport: Figure 4A). The protein was not expressed in the US11 deletion mutant of HSV1, R6604, but was present in the US11
25 rescuant of R6604, R6606 (Figure 4B and C). The kinetics of transport of US11 into axons was similar for wt and R6606 (Figure 4A and C). In neurons infected with wt HSV1, VP5 antigen was diffusely distributed in the cytoplasm of the cell body and transported throughout the axon by 24 hours (Figure 4D). The kinetics of transport of US11 and VP5 from wt HSV1 into
30 axons was similar, supporting colocalization of US11 with nucleocapsids (Figure 4A and D). In contrast, deletion of US11 in R6604 abrogated nucleocapsid transport into axons since no VP5 antigen could be detected in the axons of infected neurons (Figure 4E), although there was a similar diffuse cytoplasmic distribution of VP5 to wt HSV1 (Figure 4D and E).
35 Rescue of US11 expression in R6606 restored HSV1 nucleocapsid transport into and along axons at a rate similar to wt (Figure 4F). Anterograde

transport of gC from either wt HSV1, R6604 or R6606 into axons was unaffected (Figure 4G-I). For R6604, transmission electron microscopy at late time points (26 hours) showed large numbers of enveloped virions in the extracellular space and in the cytoplasm of the cell body of neurons, concentrated around the Golgi (Figure 5A and B). Unenveloped nucleocapsids were in variable abundance in the nuclei and sparsely scattered in the perinuclear cytoplasm, often adjacent to the Golgi (Figure 5A). Thus the absence of US11 does not prevent transport across the nuclear membrane, normal envelopment and viral egress in the cell body. Thus, there is no observable functional disruption of the tegument.

These findings suggest that there are two separate mechanisms of viral egress, one *via* the cell body and the other *via* axon termini. The absence of US11 appears to disrupt the latter pathway between the cell body and the axon. The presence of US11 in the tegument, the similar kinetics of anterograde transport of US11 and nucleocapsid VP5, and the inability of a HSV mutant deleted in US11 to be transported into axons is consistent with the hypothesis that the observed US11-uKHC interaction has a major role in mediating anterograde transport of nucleocapsids into and along axons.

Knowing how these types of viruses move in neurons to infect neurons, other cells and ultimately form lesions is an important advance and is useful for the development of antiviral strategies. Usually, during the latent state these viruses do not cause any real problems to an individual. It is during the active phase of the virus where clinical manifestations occur and suffering is caused. Preventing the actual transport of the virus down infected neurons should at least combat or prevent the clinical symptoms of re-infection. Similarly, preventing movement up the neuron may prevent the formation of latent state of the virus in ganglia or at least reduce the incidence of re-occurrence of manifestations of the disease in infected individuals.

This work raises many possibilities about the mechanisms of tegument formation, location of US11 in the tegument of HSV, the potential role of motor proteins other than kinesin(s) and homologous interactions mediating the transport of other neurotropic viruses. Inhibition of this interaction by peptides and/or peptidomimetic analogues could provide a new strategy for antiviral treatment for this and other neurotropic viruses. Incorporation of deletions into specifically attenuated live HSV (or other attenuated live

neurotropic viruses) vaccine candidates could also be useful to prevent clinical recrudescence.

5 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:

1. A method of preventing or reducing transport of a neurotropic virus within a neuron or cell, the method comprising providing to said neuron or cell a compound preventing binding between a structural tegument protein of
5 the virus and a motor protein in the neuron or cell such that virus transport in the neuron or cell is prevented or reduced.
2. The method according to claim 1 wherein the neurotropic virus is selected from the group consisting of Herpes simplex virus, varicella-zoster virus, and rabies virus.
- 10 3. The method according to claim 2 wherein the virus is Herpes simplex virus, the structural tegument protein is US11, and the motor protein is kinesin.
4. The method according to any one of claims 1 to 3 comprising providing to a neuron or cell a compound capable of altering or preventing interaction
15 between a structural tegument protein of a neurotropic virus and a motor protein in the neuron or cell.
5. The method according to claim 4 wherein the compound is a motor protein-like molecule which binds to a structural tegument protein of the virus thereby preventing the normal interaction of the virus and neuron or
20 cell.
6. The method according to claim 5 wherein the motor protein-like molecule comprises a mimic of a cellular motor protein or a part of the motor protein to which the structural tegument protein binds.
7. The method according to claim 6 wherein the virus is Herpes simplex
25 virus, the motor protein is kinesin and the motor protein-like molecule is a mimic of kinesin or a part of kinesin to which the structural tegument protein US11 of Herpes simplex virus binds.
8. The method according to claim 4 wherein the compound is a structural tegument-like molecule which binds to a motor protein of a neuron or cell
30 thereby preventing the normal interaction between the neuron or cell with the virus.
9. The method according to claim 8 wherein the structural tegument-like molecule comprises a mimic of a viral tegument protein or a part of the tegument protein to which a cellular motor protein binds.

10. The method according to claim 9 wherein the virus is Herpes simplex virus, the structural tegument protein is US11, motor protein is kinesin and the structural tegument-like molecule is a mimic of US11 or a part of US11 to which the motor protein kinesin binds.
- 5 11. A method according to any one of claims 1 to 10, wherein the method prevents or reduces transport of a neurotropic virus within a neuron.
12. An antiviral composition comprising a compound capable of preventing binding between a structural tegument protein of a neurotropic virus and a motor protein in a neuron or cell.
- 10 13. The antiviral composition according to claim 12 wherein the neurotropic virus is selected from the group consisting of Herpes simplex virus, varicella-zoster virus, and rabies virus.
14. The antiviral composition according to claim 13 wherein the virus is Herpes simplex virus, the structural tegument protein is US11, and the motor
- 15 protein is kinesin.
15. The antiviral composition according to any one of claims 12 to 14 wherein the compound a motor protein-like molecule which binds to a structural tegument protein of the virus thereby preventing the normal interaction of the virus and neuron or cell.
- 20 16. The antiviral composition according to claim 15 wherein the motor protein-like molecule comprises a mimic of a cellular motor protein or a part of the motor protein to which a structural tegument protein of a virus binds.
17. The antiviral composition according to claim 16 wherein the virus is Herpes simplex virus, the motor protein is kinesin and the motor protein-like
- 25 molecule is a mimic of kinesin or a part of kinesin to which the structural tegument protein US11 of Herpes simplex virus binds.
18. The antiviral composition according to any one of claims 12 to 14 wherein the compound is a structural tegument-like molecule which binds to a motor protein of a neuron thereby preventing the normal interaction
- 30 between the neuron or cell with the virus.
19. The antiviral composition according to claim 18 wherein the structural tegument-like molecule comprises a mimic of a viral tegument protein or a part of the tegument protein to which a cellular motor protein binds.

20. The antiviral composition according to claim 19 wherein the virus is Herpes simplex virus, the structural tegument protein is US11, motor protein is kinesin and the structural tegument-like molecule is a mimic of US11 or a part of US11 to which the motor protein kinesin binds.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT CO-OPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05410 A1

- (51) International Patent Classification⁷: A61K 35/30, 35/76, 38/17, A61P 25/00, 25/02
- (21) International Application Number: PCT/AU00/00873
- (22) International Filing Date: 20 July 2000 (20.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PQ 1719 20 July 1999 (20.07.1999) AU
- (71) Applicants (*for all designated States except US*): WESTMEAD HOSPITAL [AU/AU]; Westmead, NSW 2145 (AU). THE UNIVERSITY OF SYDNEY [AU/AU]; Sydney, NSW 2006 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): DIEFENBACH, Russell, John [AU/AU]; 6 Allambie Avenue, Northmead, NSW 2152 (AU). MIRANDA-SAKSENA, Monica [AU/AU]; Unit 20, 3 The Cottell Way, Baulkham Hills, 2153 (AU). DIEFENBACH, Eve, Margaret [AU/AU]; 6 Allambie Avenue, Northmead, NSW 2152 (AU). HOLLAND, David, James [NZ/NZ]; 5 Poto Street, Remuera, Auckland 1005 (NZ). ARMATI, Patricia, Joan [AU/AU]; 28 Wilberforce Avenue, Rose Bay, NSW 2029 (AU).
- (74) Agent: F B RICE & CO; 605 Darling Street, Balmain, NSW 2041 (AU).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NEUROTROPIC VIRUS TRANSPORT

(57) Abstract: A method of preventing or reducing transport of a neurotropic virus within a neuron, the method comprising altering or preventing interaction between a structural tegument protein of the virus and a motor protein in the neuron such that virus transport in the neuron is prevented or reduced. An antiviral composition comprising a compound capable of altering or preventing interaction between a structural tegument protein of a neurotropic virus and a motor protein in a neuron or cell.

WO 01/05410 A1

1/5




Figure 1

Figure 1 shows three Western blot panels (A, B, C) with lanes labeled at the top: Mock-infected Hep-2, HSV1-infected Hep-2, His-KHCstalk, His-KHCstalk/tail, His-KHCstalk/tail, His-KHCstalk. Panel A is stained with Anti-HSV1, showing bands at 116, 66, 45, 29, 20, and 14 KDa. Panel B is stained with Anti-VP16, showing a band at approximately 66 KDa. Panel C is stained with Anti-US11, showing a band at approximately 20 KDa. Molecular weight markers are indicated on the left of panel A.

SUBSTITUTE SHEET (RULE 26) RO/AU




Figure 3

4/5




Figure 4

5/5




Figure 5

11031492 06101
#4

RULE 61 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As below named inventor(s) we hereby declare that our residence, post office and citizenship are as stated below next to our names, and I believe: am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought on the invention entitled:

Neurotropic virus transport

the specification of which
☐ is attached hereto
☒ was filed on _____ as Application Serial No.
☒ was filed a PCT International application No. PCT/AU00/00873 on 20 July 2000
and (if applicable to US or PCT application) was amended on 14 June 2001

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. We acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(e). We hereby state foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below all have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed, or if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s)			Priority Claimed	
PQ 1719	Australia	20 July 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
PCT/AU00/00873	PCT	20 July 2000	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

We hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international application(s) listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior application in the manner provided by the first paragraph of 35 U.S.C. 112, we acknowledge the duty to disclose material information as claimed in 37 C.F.R. 1.54(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

Prior U.S./PCT Application(s)		
(Application Serial no.)	(Filing Date)	(Status: patented, pending, abandoned)

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information are believed to be true; and further that these statements were made with the knowledge that willful false statements and thus like as made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of his application or any patent issued thereon.

And we hereby appoint **NICON & VANDERHISE P.C.**, 1104 North Glebe Road, 5th Floor, Arlington, VA 22201-4114, telephone number (703) 86-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 2537; Larry S. Nixon, 25640; Robert A. Vandervort, 27026; James T. Houser, 30184; Robert W. Farris, 3113; Richard G. Beahm, 2279; Mark B. Tushnet, 32348; Michael I. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spawen, 27393; Leonard C. Mitchell, 2900; Duane M. Byers, 3363; Paul J. Xenon, 33626; Jeffrey H. Nelson, 30481; John R. Lestera, 3149; H. Warren Burton, Jr., 29364; Thomas E. Byrne, 32055.

Inventor's Signature: R. J. Diefenbach
Inventor's Name: Russell John Diefenbach
Residence: 6 Allambie Avenue, Northmead, New South Wales, 2153, Australia
Citizenship: Australian
Post Office Address: 6 Allambie Avenue, Northmead, New South Wales, 2153, Australia

Date: 2/2/2002.

AUX

For additional Inventor(s) check box ☒

SCANNED #

17

1-00

-2-

2-00

Inventor's Signature
Inventor's Name
Residence:
Citizenship:
Post Office Address:

*Monica Miranda H*Monica Miranda-SakumaUnit 21, 5 The Cottrell Way, Baulkham Hills, New South Wales, 2153, Australia
Australian

Unit 21, 5 The Cottrell Way, Baulkham Hills, New South Wales, 2153, Australia

Date: 21/2/02

AUX

3-00

Inventor's Signature
Inventor's Name
Residence:
Citizenship:
Post Office Address:

*S. Dieckbach*Iris Margaret Dieckbach8 Allambie Avenue, Northmead, New South Wales, 2152, Australia
Australian

8 Allambie Avenue, Northmead, New South Wales, 2152, Australia

Date: 21/2/2002

AUX

4-00

Inventor's Signature
Inventor's Name
Residence:
Citizenship:
Post Office Address:

*D. Holland*David James Holland5 Peto Street, Rotorua, Auckland, 3002, New Zealand
New Zealand

5 Peto Street, Rotorua, Auckland, 3002, New Zealand

Date: 1/3/2002

NZX

5-00

Inventor's Signature
Inventor's Name
Residence:
Citizenship:
Post Office Address:

*A. Cunningham*Anthony Lawrence Cunningham22 Rathfield Road, Chalfonts, New South Wales, 2126, Australia
Australian

22 Rathfield Road, Chalfonts, New South Wales, 2126, Australia

Date: 21/2/2002.

AUX

6-00

Inventor's Signature
Inventor's Name
Residence:
Citizenship:
Post Office Address:

*M. Patchell*41 Darcy Road, Westmead, New South Wales, 2145, Australia
Australian

41 Darcy Road, Westmead, New South Wales, 2145, Australia

Date: 5/6/2002

AUX

Inventor's Signature
Inventor's Name
Residence:
Citizenship:
Post Office Address:

*P. Jean Arnaud*28 Wilberforce Avenue, Rose Bay, New South Wales, 2029, Australia
Australian

28 Wilberforce Avenue, Rose Bay, New South Wales, 2029, Australia

Date:

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As below named inventor(s) we hereby declare that our residence, post office and citizenship are as stated below next to our name(s) and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought on the invention entitled:

Neurotropic virus transport

the specification of which
☐ is attached hereto
☒ was filed as
☒ was filed as PCT International application No. PCT/AU00/00873 on 20 July 2000
 and (if applicable to US or PCT application) was amended on 14 June 2001

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. We acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(e). We hereby claim foreign priority benefit under 35 U.S.C. 119/355 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed, or if no priority is claimed, before the filing date of this application:

Prior Foreign Applications			Priority Claimed	
PQ 1719	Australia	20 July 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
PCT/AU00/00873	PCT	20 July 2000	<input checked="" type="checkbox"/>	<input type="checkbox"/>
[Number]	[Country]	[Day/Month/Year Filed]	<input type="checkbox"/>	<input type="checkbox"/>
			Yes	No

We hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international application(s) listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior application in the manner provided by the first paragraph of 35 U.S.C. 112, we acknowledge the duty to disclose material information as claimed in 37 C.F.R. 1.51(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

Prior U.S./PCT Application(s)

[Application Serial No.]	[Filing Date]	[Status: patented, pending, abandoned]

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And we hereby appoint **NIKON & VANDERHYE PC**, 1104 North Glabe Road, 8th Floor, Arlington, VA 22201-4014, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively as attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent and Trade Mark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 23640; Robert A. Vandehey, 27076; James T. Browner, 30184; Robert W. Faria, 31132; Richard O. Beale, 22770; Mark E. Yustman, 32148; Michael I. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spence, 27393; Leonard C. Mitchell, 29009; Duane M. Byers, 33363; Paul J. Kenon, 33626; Jeffrey H. Nelson, 30481; John R. Lastova, 31499; H. Warren Swann, Jr., 29364; Thomas E. Byrne, 32105.

Inventor's Signature

Inventor's Name:

Residence:

Citizenship:

Post Office Address:

Russell John Didenbach

Russell John Didenbach

6 Allambie Avenue, Northmead, New South Wales, 2153, Australia

Australian

6 Allambie Avenue, Northmead, New South Wales, 2153, Australia

Date: 2/12/2002

For additional inventor, check box ☒

- 2 -

Inventor's Signature
Inventor's Name:
Residence:
Citizenship:
Post Office Address:

Maria Mandat

Date: 21/2/00

Monclouk and Sakreou

Unit 21, 3 The Cottrell Way, Baulkham Hills, New South Wales, 2153, Australia

Australian

Unit 21, 3 The Cottrell Way, Baulkham Hills, New South Wales, 2153, Australia

Inventor's Signature
Inventor's Name:
Residence:
Citizenship:
Post Office Address:

S. Diefenbach

Date: 21/2/2002

Sve Murx and Diefenbach

5 Alland Avenue, Northmead, New South Wales, 2153, Australia

Australia

5 Alland Avenue, Northmead, New South Wales, 2153, Australia

Inventor's Signature
Inventor's Name:
Residence:
Citizenship:
Post Office Address:

P. Holland

Date: 1/3/2002

David James Holland

5 Puke Street, Rotorua, Auckland, 3006, New Zealand

New Zealand

5 Puke Street, Rotorua, Auckland, 3006, New Zealand

Inventor's Signature
Inventor's Name:
Residence:
Citizenship:
Post Office Address:

Anthony Lawrence Channingham

Date: 21/2/2002

Anthony Lawrence Channingham

22 Judd Island Road, Cheltenham, New South Wales, 2119, Australia

Australian

22 Judd Island Road, Cheltenham, New South Wales, 2119, Australia

Inventor's Signature
Inventor's Name:
Residence:
Citizenship:
Post Office Address:

Mark Mcfold

Date:

41 Oakley Road, Westmead, New South Wales, 2145, Australia

Australian

41 Oakley Road, Westmead, New South Wales, 2145, Australia

7-00
Inventor's Signature
Inventor's Name:
Residence:
Citizenship:
Post Office Address:

P. Armati

Date: 30.05.2002

Dr. Joao Armati

20 The Terrace Avenue, Rose Bay, New South Wales, 2029, Australia

Australian

20 The Terrace Avenue, Rose Bay, New South Wales, 2029, Australia

AUX